Related Experiment Video

Updated: Sep 20, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K

Vimseltinib: First Approval

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|May 25, 2025
PubMed

Insights

Vimseltinib is a new oral kinase inhibitor approved for tenosynovial giant cell tumor (TGCT). It targets colony-stimulating factor 1 receptor (CSF1R), offering a new treatment option for TGCT patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Colony-stimulating factor 1 receptor (CSF1R) activity is implicated in the pathogenesis of tenosynovial giant cell tumor (TGCT).
  • Targeting CSF1R presents a potential therapeutic strategy for managing TGCT.

Purpose of the Study:

  • To summarize the development milestones of vimseltinib.
  • To highlight the first approval of vimseltinib for TGCT treatment.

Main Methods:

  • Vimseltinib is an orally administered kinase inhibitor targeting CSF1R.
  • Development involved investigating CSF1R as a therapeutic target.

Main Results:

  • Vimseltinib received its first US approval in February 2025.
  • The approval is for adult patients with symptomatic TGCT.

Conclusions:

  • Vimseltinib offers a novel oral treatment for TGCT.
  • The drug is indicated for patients where surgery may cause significant functional impairment or morbidity.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
267